Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045748 | 1.00 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045778 | 1.00 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045722 | 1.00 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045726 | 0.87 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045829 | 0.87 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045675 | 0.87 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL6045834 | 0.87 | ADCY5 (1.00) | ADCY5 | |
| SCHEMBL111590 | 0.82 | ADCY5 (0.74) | ADCY5 | |
| SCHEMBL5997273 | 0.82 | ADCY5 (0.74) | ADCY5 | |
| SCHEMBL5997270 | 0.82 | ADCY5 (0.74) | ADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | ADCY5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.